Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: J Allergy Clin Immunol. 2011 Sep 8;128(5):977–82.e1-2. doi: 10.1016/j.jaci.2011.07.018

Table 1.

Baseline characteristics relating to frequency of NASRA

Characteristic: Number of annualized NASRA P value
0 NASRA
(79 subjects)
1–12 NASRA
(136 subjects)
≥13 NASRA
(69 subjects)
Male gender, n (%) 50 (63.3) 88 (64.7) 36 (52.5) NS
BMI 19.5 ± 4.0 20.1 ± 4.8 20.3 ± 5.8 NS
Non-Caucasian race*, n (%) 13 (16.5) 23 (16.9) 22 (31.2) 0.03
Age at randomization (years) 10.0 ± 2.2 9.8 ± 2.3 9.7 ± 2.0 NS
Age at onset of asthma (years) 3.6 ± 2.8 3.1 ± 2.7 3.0 ± 2.7 NS
Number of NASRA/subject during the 14 day run-in period 0.10 ± 0.3 0.58 ± 1.1 1.3 ± 1.5 <0.0001
Number of asthma-free days/subject during the 14-day run-in period 4.7 ± 3.7 3.5 ± 3.0 3.4 ± 3.0 0.008
AM PEF during run-in period (L/min) 252.0 ± 72.0 244.8 ± 71.8 248.6 ± 58.4 NS
PM PEF during run-in period (L/min) 256.8 ± 69.8 251.9 ± 74.1 254.7 ± 59.1 NS
PEF variability during run-in period (%) 9.3 ± 4.6 10.2 ± 5.8 9.8 ± 4.7 NS
Pre-BD FEV1 (% predicted) 98.8 ± 11.2 96.3 ± 12.8 98.3 ± 12.4 NS
Pre-BD FEV1/FVC (%) 80.9 ± 7.5 78.8 ± 7.7 81.3 ± 7.8 NS
Maximum BD response (%) 9.9 ± 7.3 10.9 ± 7.5 11.1 ± 8.3 NS
Peripheral Blood Eosinophils (%) 5.4 ± 3.6 6.1 ± 4.6 6.4 ± 3.8 NS
PC20 (mg/mL), median (Quartile 1, Quartile 3) 1.1 (0.4, 2.6) 0.8 (0.3, 2.5) 0.8 (2, 2.9) NS
FeNO (ppb), median (Quartile 1, Quartile 3) 24.8 (9.7, 50.5) 22.7 (12.8, 51.3) 31.9 (12.6, 58.0) NS
IgE (IU/mL), median (Quartile 1, Quartile 3) 129.0 (40.9, 363.0) 164 (61.7, 363.0) 176.0 (69.0, 415.0) NS
At least 1 positive skin test, n (%) 58 (73.4) 109 (80.2) 55 (79.7) NS
      Medication use in prior year:
Inhaled or nebulized corticosteroids, n (%) 44 (55.7) 80 (58.5) 36 (52.2) NS
Fluticasone/salmeterol combination, n (%) 10 (12.7) 15 (11.4) 10 (13.7) NS
Montelukast, n (%) 28 (35.4) 52 (38.2) 15 (21.7) NS

Data represent mean ± SD except as noted.

*

Non-Caucasian race was 73% Black, 17% American Indian, 3% Asian and 7% Pacific Islander.